Literature DB >> 33760943

Clinical application of circulating tumor DNA in breast cancer.

Jeffrey Chun Hin Chan1, James Chung Hang Chow2, Connie Hoi Man Ho3, Therese Yue Man Tsui2, William C Cho4.   

Abstract

BACKGROUND: The recent advancement in massively parallel sequencing technologies has empowered liquid biopsies, in particular circulating tumor DNA (ctDNA) analysis, to be the new paradigm in personalized cancer management. Plasma ctDNA detection overcomes the current limitations in tumor tissue procurement and serves as a convenient and non-invasive method to capture tumor heterogeneity and genetic evolution along patients' cancer journey. In breast cancer, the current clinical application of ctDNA includes real-time monitoring of tumor response, detection of drug-resistant clones, assessing dynamic variations in tumor mutational landscape, identifying actionable mutations, detecting minimal residual disease and screening of early tumor.
PURPOSE: This review aims to summarize the current clinical evidence of ctDNA application in the management of breast cancer.

Entities:  

Keywords:  Breast cancer; Circulating tumor DNA; ESR1 mutations; HER2 amplification; Liquid biopsy; PIK3CA mutations

Mesh：

Substances：

Year:  2021        PMID： 33760943     DOI： 10.1007/s00432-021-03588-5

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  93 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Authors:  Katrien Berns; Hugo M Horlings; Bryan T Hennessy; Mandy Madiredjo; E Marielle Hijmans; Karin Beelen; Sabine C Linn; Ana Maria Gonzalez-Angulo; Katherine Stemke-Hale; Michael Hauptmann; Roderick L Beijersbergen; Gordon B Mills; Marc J van de Vijver; René Bernards
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

3.  Genomic characterization of metastatic breast cancers.

Authors:  François Bertucci; Charlotte K Y Ng; Anne Patsouris; Thomas Filleron; Christophe Le Tourneau; Fabrice André; Nathalie Droin; Salvatore Piscuoglio; Nadine Carbuccia; Jean Charles Soria; Alicia Tran Dien; Yahia Adnani; Maud Kamal; Séverine Garnier; Guillaume Meurice; Marta Jimenez; Semih Dogan; Benjamin Verret; Max Chaffanet; Thomas Bachelot; Mario Campone; Claudia Lefeuvre; Herve Bonnefoi; Florence Dalenc; Alexandra Jacquet; Maria R De Filippo; Naveen Babbar; Daniel Birnbaum
Journal:  Nature       Date:  2019-05-22       Impact factor: 49.962

4.  Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

Authors:  Fabrice André; Eva Ciruelos; Gabor Rubovszky; Mario Campone; Sibylle Loibl; Hope S Rugo; Hiroji Iwata; Pierfranco Conte; Ingrid A Mayer; Bella Kaufman; Toshinari Yamashita; Yen-Shen Lu; Kenichi Inoue; Masato Takahashi; Zsuzsanna Pápai; Anne-Sophie Longin; David Mills; Celine Wilke; Samit Hirawat; Dejan Juric
Journal:  N Engl J Med       Date:  2019-05-16       Impact factor: 91.245

5.  Detection of circulating tumor DNA in early- and late-stage human malignancies.

Authors:  Chetan Bettegowda; Mark Sausen; Rebecca J Leary; Isaac Kinde; Yuxuan Wang; Nishant Agrawal; Bjarne R Bartlett; Hao Wang; Brandon Luber; Rhoda M Alani; Emmanuel S Antonarakis; Nilofer S Azad; Alberto Bardelli; Henry Brem; John L Cameron; Clarence C Lee; Leslie A Fecher; Gary L Gallia; Peter Gibbs; Dung Le; Robert L Giuntoli; Michael Goggins; Michael D Hogarty; Matthias Holdhoff; Seung-Mo Hong; Yuchen Jiao; Hartmut H Juhl; Jenny J Kim; Giulia Siravegna; Daniel A Laheru; Calogero Lauricella; Michael Lim; Evan J Lipson; Suely Kazue Nagahashi Marie; George J Netto; Kelly S Oliner; Alessandro Olivi; Louise Olsson; Gregory J Riggins; Andrea Sartore-Bianchi; Kerstin Schmidt; le-Ming Shih; Sueli Mieko Oba-Shinjo; Salvatore Siena; Dan Theodorescu; Jeanne Tie; Timothy T Harkins; Silvio Veronese; Tian-Li Wang; Jon D Weingart; Christopher L Wolfgang; Laura D Wood; Dongmei Xing; Ralph H Hruban; Jian Wu; Peter J Allen; C Max Schmidt; Michael A Choti; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Luis A Diaz
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

6.  Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  José Baselga; Seock-Ah Im; Hiroji Iwata; Javier Cortés; Michele De Laurentiis; Zefei Jiang; Carlos L Arteaga; Walter Jonat; Mark Clemons; Yoshinori Ito; Ahmad Awada; Stephen Chia; Agnieszka Jagiełło-Gruszfeld; Barbara Pistilli; Ling-Ming Tseng; Sara Hurvitz; Norikazu Masuda; Masato Takahashi; Peter Vuylsteke; Soulef Hachemi; Bharani Dharan; Emmanuelle Di Tomaso; Patrick Urban; Cristian Massacesi; Mario Campone
Journal:  Lancet Oncol       Date:  2017-05-30       Impact factor: 41.316

7.  The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies.

Authors:  Lindsay Angus; Marcel Smid; Saskia M Wilting; Job van Riet; Arne Van Hoeck; Luan Nguyen; Serena Nik-Zainal; Tessa G Steenbruggen; Vivianne C G Tjan-Heijnen; Mariette Labots; Johanna M G H van Riel; Haiko J Bloemendal; Neeltje Steeghs; Martijn P Lolkema; Emile E Voest; Harmen J G van de Werken; Agnes Jager; Edwin Cuppen; Stefan Sleijfer; John W M Martens
Journal:  Nat Genet       Date:  2019-09-30       Impact factor: 38.330

8.  Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease.

Authors:  Timothy M Butler; Katherine Johnson-Camacho; Myron Peto; Nicholas J Wang; Tara A Macey; James E Korkola; Theresa M Koppie; Christopher L Corless; Joe W Gray; Paul T Spellman
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

9.  A global reference for human genetic variation.

Authors:  Adam Auton; Lisa D Brooks; Richard M Durbin; Erik P Garrison; Hyun Min Kang; Jan O Korbel; Jonathan L Marchini; Shane McCarthy; Gil A McVean; Gonçalo R Abecasis
Journal:  Nature       Date:  2015-10-01       Impact factor: 49.962

10.  Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients.

Authors:  Violette Allouchery; Ludivine Beaussire; Anne Perdrix; David Sefrioui; Laetitia Augusto; Cécile Guillemet; Nasrin Sarafan-Vasseur; Frédéric Di Fiore; Florian Clatot
Journal:  Breast Cancer Res       Date:  2018-05-16       Impact factor: 6.466
View more
  1 in total

Review 1.  Unveiling the Potential of Liquid Biopsy in HER2-Positive Breast Cancer Management.

Authors:  Ana Godoy-Ortiz; Alfonso Alba-Bernal; Javier Pascual; Iñaki Comino-Méndez; Emilio Alba
Journal:  Cancers (Basel)       Date:  2022-01-24       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.